Pemetrexed/Carboplatin Non-Small Cell Lung Cancer (NSCLC) Elderly Patients

• Status: Completed
• Trial end date: 2009-11-01
• Target enrollment: 0
• Participant gender: All

Summary

A phase II study to evaluate the efficacy and safety profile of the combination of Pemetrexed and Carboplatin in elderly patients with advanced non-small cell lung cancer

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Carboplatin; Pemetrexed

Criteria

Inclusion Criteria:

• Pathologically confirmed Non Small Cell Lung Cancer Stage IIIb (not amenable to radiotherapy treatment) or Stage IV

• No previous chemotherapy for lung cancer

• Men and women > or = 70 years

• At least one uni-dimensionally measurable lesion (Response Evaluation Criteria In Solid Tumors [RECIST]criteria)

• Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 1

Exclusion Criteria:

• Treatment within the last 30 days with a drug that has not received regulatory approval

• Serious systemic disorders

• Inability to discontinue administration of aspirin or anti-inflammatory non steroid

• Concurrent administration of any other antitumor therapy

• Brain metastasis